ALHEMO

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

5 competitors in Haemophilia a

#DrugCompanyPhaseTrials

1

Efanesoctocog Alfa

Sanofi

Phase 3

12

ALHEMO

Novo Nordisk

Phase 3

23

Mim8

Novo Nordisk

Phase 3

24

Nuwiq

Octapharma

Phase 3

25

NNC0442-0344 a

Novo Nordisk

Phase 1

1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Haemophilia A2 trials

Trial Investigating Safety, Pharmacokinetics and Pharmacodynamics of Concizumab Administered Subcutaneously to Haemophilia A Subjects

Completed·Novo Nordisk·Phase 1·NCT02490787·24 enrolled

Open-label Study Investigating Efficacy, Safety and Pharmacokinetics of Concizumab Prophylaxis in Children Below 12 Years With Haemophilia A or B With or Without Inhibitors

Active, not recruiting·Novo Nordisk·Phase 3·NCT05135559·153 enrolled

Haemophilia A Without Inhibitors2 trials

A Trial Evaluating Efficacy and Safety of Prophylactic Administration of Concizumab in Patients With Severe Haemophilia A Without Inhibitors

Completed·Novo Nordisk·Phase 2·NCT03196297·36 enrolled

Efficacy and Safety of Concizumab Prophylaxis in Patients With Haemophilia A or B Without Inhibitors

Active, not recruiting·Novo Nordisk·Phase 3·NCT04082429·156 enrolled

Treatment1 trial

Post-marketing Surveillance (Special Use-results Surveillance) on Treatment With Alhemo

Enrolling by invitation·Novo Nordisk··NCT06831734·30 enrolled

Efficacy and Safety1 trial

A Trial Evaluating the Efficacy and Safety of Prophylactic Administration of Concizumab in Haemophilia A and B Patients With Inhibitors

Completed·Novo Nordisk·Phase 2·NCT03196284·26 enrolled

Haemophilia B With Inhibitors1 trial

Post-Marketing Surveillance (All Case Surveillance) on Treatment With Alhemo® in Patients With Haemophilia A or Haemophilia B With Inhibitors

Enrolling by invitation·Novo Nordisk··NCT06285071·23 enrolled

2 more indications

Congenital Haemophilia1 trial

Concizumab Compassionate Use Programme for Patients With Congenital Haemophilia

Available·Novo Nordisk··NCT04921956

Haemophilia A With Inhibitors1 trial

Efficacy and Safety of Concizumab Prophylaxis in Patients With Haemophilia A or B With Inhibitors

Active, not recruiting·Novo Nordisk·Phase 3·NCT04083781·134 enrolled

Regulatory

FDA Approval Timeline[4]

Details

Drug Info

Related News